JPL Wealth Management’s Myriad Genetics MYGN Stock Holding History

JPL Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9	Closed	-$41	–	1942
2026 Q1	$41	Buy	+9	New	+$47	﹤0.01%	1514

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JPL Wealth Management's MYGN Position: Q2 2026 in Review

JPL Wealth Management sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 9 shares — an estimated $41 sold.

JPL Wealth Management first reported a position in MYGN in Q1 2026 and held it in 1 quarter. The position peaked at $41 in Q1 2026. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

JPL Wealth Management reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
JPL Wealth Management sold 9 Myriad Genetics shares in Q2 2026, an estimated $41.
JPL Wealth Management first reported a position in Myriad Genetics in Q1 2026 and held it in 1 quarter.
JPL Wealth Management's Myriad Genetics position peaked at $41 in Q1 2026.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on JPL Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.